1 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals WHO’s Role in Assuring the Quality Safety and Efficacy of Medicines:

Slides:



Advertisements
Similar presentations
Quality Assurance Processes for TB Drugs. GDF Quality Assurance Processes.
Advertisements

1 WHOs Role in Assuring the Quality Safety and Efficacy of Drugs: Introduction Lembit Rägo, MD, PhD, Coordinator Quality Assurance and Safety: Medicines.
WHOs Normative Work in the Field of Pharmaceuticals - introduction Lembit Rägo, MD, PhD, Coordinator Quality Assurance and Safety: Medicines Essential.
WHO update on: Guidelines for the selection of RH medicines and prequalification of priority RH medicines Medicines Policy and Standards Health Technology.
Prequalification and Quality Monitoring of anti-malaria products Andre van Zyl, M. Pharm. Project Manager Health Technology and Pharmaceuticals Cluster,
UNITED SPINAL ASSOCIATION AUGUST, 2014 Biologics & Biosimilars: An Overview 1.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Christine Simmon Senior Vice President, Policy & Strategic Alliances Generic Pharmaceutical Association November 6, 2014 Biologics Naming.
1 Department of Essential Medicines and Pharmaceutical Policies, Health Systems and Services World Health Organization's Prequalification Program for medicines.
ICH-GCG June 2009 Pan American Health Organization CURRENT STATUS OF PAN AMERICAN NETWORK FOR DRUG REGULATORY HARMONIZATION (PANDRH): James Fitzgerald.
Short Update WHO Essential Medicines and Health products IPC Meeting 4 to 6 June 2014.
1 FDA Thailand By HIV Module/Marketing Group Mr. Manaswee Arayasiri.
NATIONAL DRUG AUTHORITY - UGANDA | Slide 1 of February 2010, Geneva, Switzerland How the African NMRAs are benefiting from the WHO medicines prequalification.
1 WHO Programme for International Drug Monitoring & the Uppsala Monitoring Centre Shanthi Pal and Mary Couper Quality Assurance and Safety of Medicines.
Tanzania, August, 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Guidelines and Tools available TRS 937 and BTIF (Bioequivalence Trial Information Form)
Documentation of bioequivalence Drs. J. Welink Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009.
WHO Traditional Medicine Strategy and Guidelines Dr Arvind Mathur MD, DHA, DNB Cluster Coordinator Family & Community Health WHO-India World Health Organisation.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Update and future directions for prequalification of medicines WHO HQ, Geneva, 4 February 2008 Dr Lembit Rägo Coordinator Quality Assurance and Safety:
Safe and Appropriate Use of Injection Activities of WHO’s Department of Blood Safety and Clinical Technology (BCT) Yvan Hutin Annual SIGN Meeting New Delhi.
Bioequivalence and Bioavailability Working Group.
Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.
QUALITY REPRODUCTIVE HEALTH SUPPLIES Dr Hans V. Hogerzeil Director Essential Medicines & Pharmaceutical Policies.
General Principles of Medicines Regulation Dr Lembit Rägo Coordinator Quality Assurance and Safety: Medicines (QSM) Medicines Policy and Standards (PSM)
Regulation of medicines and other health technologies. The future of regulation, where are we going? EMP TBS November 2014, Geneva Dr Lembit Rägo Head,
OVERVIEW OF THE ZIMBABWE NATIONAL MEDICINES POLICY Dr C E Ndhlovu, M Med Sci, FRCP Chairperson, NMTPAC Deputy Dean, UZCHS National workshop, Jan 22-23,
1 TG Dekker – WHO, UkraineOctober 2005 Introduction to Dossier Requirements and Guidelines within the Prequalification Project (quality part) World Health.
NRA in BTSs of the EMR Dr. Nabila E. Metwalli Regional Advisor / Blood Safety WHO / EMRO Cairo, Egypt and Dr. Abdel Aziz Saleh WHO / EMRO Advisor.
ACCESS TO MEDICINES - POLICY AND ISSUES
Meeting for EU Generic Manufacturers and EU MA holders for generic medicines, Copenhagen, 26 November 2009 Generics approved by stringent regulatory authorities:
| Slide 1 of 25 April 2007 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Protea Hotel Victoria Junction, Waterfront.
Dr Shanthi Pal Quality Assurance and Safety of Medicines WHO
WHO Workshop on Prequalification of Medicines Programme, Abu Dhabi, October, 2010 Regulatory principles reflected in practice of WHO PQP Milan Smid,
Slide 1 of 10D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
1 Department of Essential Medicines and Pharmaceutical Policies Introduction to Medicines Quality Assurance and Safety Dr Lembit Rägo Coordinator Quality.
WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September 2010 Selection of comparators Compiled by Jan Welink WHO Workshop.
Quality & Safety of Generic Drugs in the World Market World Bank Conference “Good Intentions – Bad Drugs” March 10, 2005 Washington, D.C. Christine Simmon.
MEDICATION MANAGEMENT P&T COMMITTEE AND FORMULARY MANAGEMENT EMTENAN ALHARBI, Msc CLINICAL PHARMACIST.
WHO Prequalification of Medicines: a gateway to the global pharmaceutical market Introduction 28 June 2014, Shanghai Milan Smid.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
Dr Mary Couper Quality Assurance and Safety of Medicines WHO
“Supporting the Industry through Communication” The pharmaceutical industry is committed to the research, development, quality manufacturing and logistics.
1 Department of Essential Medicines and Pharmaceutical Policies Medicines Regulation: Introduction Dr Lembit Rägo Coordinator Quality Assurance and Safety:
Chapter Dental Public Health & Research Contemporary Practice for the Dental Hygienist Copyright ©2011 by Pearson Education, Inc. All rights reserved.
PHARMACOVIGILANCE PLAN FOR TANZANIA PREPARED BY EMMA & MARY 10 TH SEPTEMBER 2004.
WHO Medicines Strategy Progress: Priorities: Dr Guitelle Baghdadi Essential Drugs and Medicines Policy World Health Organization November.
WHO Regional Workshop on Good Manufacturing Practices for Blood Establishments Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines.
Dr R. Balocco Mattavelli, INN Programme Manager Informal Consultation on Medical devices, March 2011 INN Programme Dr Raffaella Balocco Mattavelli.
2010 James Fitzgerald Senior Advisor, Medicines and Health Technologies PAHO/WHO rd St Washington DC USA International Cooperation in Quality.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
Implementation of PANDRH Guidelines NAFTA Region VI PANDRH Conference Brasilia, July 2-8, 2011 Justina Molzon -- US Food and Drug Administration Mike Ward.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
Efficacy and Safety of Medicines
EAST AFRICAN COMMUNITY MEDICINES REGULATORY HARMONIZATION (EAC-MRH) PROJECT PROGRESS NAIROB I - KENYA By: EAC - Secretariat.
DIA Clinical Safety and Pharmacovigilance Community
Quality of Medicines: Introduction Tuesday, 17 November 2009
Quality Assurance and Safety of Medicines
Medicines Regulation: Introduction
Quality Problems with Antimalarials
WHO’s Role in Assuring the Quality Safety and Efficacy of Drugs:
Assessment of Medicines
Dr Manisha Shridhar Regional Advisor WHO-SEARO
Prequalification of HIV/AIDS products and manufacturers
Quality Assurance and Safety of Medicines
Pharmacovigilance.
An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
A FRIENDLY REMINDER ON OTC DRUGS. DRUG REGULATIONS IN THE PHILIPPINES.
An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
Presentation transcript:

1 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals WHO’s Role in Assuring the Quality Safety and Efficacy of Medicines: Introduction Lembit Rägo, MD, PhD Coordinator, Quality Assurance and Safety: Medicines (QSM) Acting Coordinator, Quality Assurance and Safety: Blood Products and Related Biologicals (QSD) Essential Drugs and Medicines Policy Health Technology and Pharmaceuticals Cluster World Health Organization EDM Technical Briefing 2006

2 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals This block of presentations gives n General introduction to quality and safety issues n Detailed overview of WHO's normative activities in the area of medicines (excluding biologicals) quality (QSM) n Introductory presentation on the area of quality assurance and safety of blood products and related biologicals (QSD)

3 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals The rest of the QSM activities n Later in the programme ä Prequalification ä Safety - Pharmacovigilance n Not covered by this training course ä INN programme ä ATC/DDD classification and its use ä Scheduling controlled substances and access to controlled medicines ä …

4 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals Standards for medicines n How to judge that medicines are what we expect them to be? n In case of many products people take their judgements at least partly based on what they see, smell or taste …or hear

5 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals Usual perceptions may not help to make judgments about medicines … SmellAppearance Taste

6 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals In case of medicines they all look nice, mostly do not have any smell, some may have bad taste…and are increasingly marketed even through internet (see example below, note that selling medicines via internet may be illegal and products may be counterfeit or substandard)

7 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals Why medicines are special category of products? n Consumers, patients and health care workers have limited capacity to judge there ä SAFETY ä QUALITY ä EFFICACY

8 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals Are all medicines safe, effective and meet quality criteria? n No, they are not n Some are safe, but not effective or necessarily meet the quality criteria n Some may be effective, meet quality criteria but are not safe n Some meet quality criteria but are not necessarily safe or have any efficacy

9 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals Quality - Safety n Some safety parameters are determined by quality n Some safety parameters are determined by the intrinsic properties of active pharmaceutical ingredient ä However, in fact QUALITY in general perception (and often in policy documents) is incorporating also expectations for efficacy and safety without necessarily saying so

10 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals What type of medicines we have? n Originator products n Multisource (generic) products ä KEY – INTERCHANGEABILITY, more important THERAPEUTIC INTERCHNGEABILITY ä ALL LITERATURE IS BASED ON ORGINATORS ä No interchangeability – NEED FOR NEW SAFETY and EFFICACY DATA, NEW BOOKS HAVE TO BE WRITTEN

11 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals What type of regulations exist and how they differ? n For innovator products proof of QUALITY, SAFETY and EFFICACY is needed n For multisource products QUALITY, safety and efficacy data is referred to the originator providing only evidence about interchangeability (bioequivalence, clinical testing, in limited cases dissolution data)

12 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals Regulations: Global vs National n National regulations still differ a lot n What is ICH and what it is not? n Regional harmonization initiatives n Do global norms exist for generics?

13 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals Who sets the standards? Is the WHO Involved? n WHO has the unique mandate to set standards n WHO Constitution (Chapter II, Article 2), inter alia, states (6): ä In order to achieve its objective, the functions of the organization shall be: … to develop, establish and promote international standards with respect to food, biological, pharmaceutical and similar products; Example of WHO work from 1966

14 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals Is quality of medicines a problem? n Yes, a HUGE problem n If we would have the same compliance with norms and quality in aircraft industry Globally as we have with medicines, perhaps n ä approximately 25% planes would not take off the grounds (no or very poor treatment effect, can also potentially kill if disease deadly) ä 5-10% would crash and injure or kill the people (toxicity, severe adverse reactions etc. )

15 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals What WHO is doing? n Norms and standards, nomenclatures ä International Pharmacopoeia ä International Nonproprietary Names (INN) ä ATC/DDD classification ä … n Regulatory guidelines ä Good Manufacturing Practice; Good Clinical Practice etc. ä Comprehensive set of guidelines for registering generic drugs ä … n Information exchange ä WHO Drug Information (quarterly) ä WHO pharmaceutical Newsletter ä WHO Rapid Alerts ä International Conference of Drug Regulatory Authorities (ICDRA) – usually more than 100 countries represented ä …. n Capacity building and training ä GMP training courses ä Courses on how to assess generic drugs ä Courses on pharmacovigilance ä ….

16 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals Conclusions n A lot of good work ongoing but …. ä Limited capacity to advertise, promote, inform etc. ä Limited resources to build capacity in countries n Please, for more information: l